![]() |
Name |
notoamide B
|
Molecular Formula | C26H29N3O4 | |
IUPAC Name* |
(1'S,3R,7'S,9'S)-7,7,10',10'-tetramethylspiro[1H-pyrano[2,3-g]indole-3,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,2',14'-trione
|
|
SMILES |
CC1(C=CC2=C(O1)C=CC3=C2NC(=O)[C@@]34C[C@]56[C@H](C4(C)C)C[C@@]7(CCCN7C5=O)C(=O)N6)C
|
|
InChI |
InChI=1S/C26H29N3O4/c1-22(2)10-8-14-16(33-22)7-6-15-18(14)27-20(31)25(15)13-26-17(23(25,3)4)12-24(19(30)28-26)9-5-11-29(24)21(26)32/h6-8,10,17H,5,9,11-13H2,1-4H3,(H,27,31)(H,28,30)/t17-,24-,25+,26-/m0/s1
|
|
InChIKey |
RNWRZMCJFWSZOX-OFVWMMNVSA-N
|
|
Synonyms |
notoamide B; (-)-Notoamide B; Notamide B; CHEMBL2042022; DTXSID801046203; (1'S,3R,7'S,9'S)-7,7,10',10'-tetramethylspiro[1H-pyrano[2,3-g]indole-3,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,2',14'-trione; 937791-52-1
|
|
CAS | 937791-52-1 | |
PubChem CID | 16127923 | |
ChEMBL ID | CHEMBL2042022 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 447.5 | ALogp: | 2.1 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.7 | Aromatic Rings: | 8 |
Heavy Atoms: | 33 | QED Weighted: | 0.637 |
Caco-2 Permeability: | -5.304 | MDCK Permeability: | 0.00002520 |
Pgp-inhibitor: | 0.751 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.078 | 20% Bioavailability (F20%): | 0.652 |
30% Bioavailability (F30%): | 0.908 |
Blood-Brain-Barrier Penetration (BBB): | 0.609 | Plasma Protein Binding (PPB): | 90.39% |
Volume Distribution (VD): | 1.09 | Fu: | 8.68% |
CYP1A2-inhibitor: | 0.015 | CYP1A2-substrate: | 0.724 |
CYP2C19-inhibitor: | 0.238 | CYP2C19-substrate: | 0.901 |
CYP2C9-inhibitor: | 0.628 | CYP2C9-substrate: | 0.504 |
CYP2D6-inhibitor: | 0.28 | CYP2D6-substrate: | 0.137 |
CYP3A4-inhibitor: | 0.936 | CYP3A4-substrate: | 0.93 |
Clearance (CL): | 2.912 | Half-life (T1/2): | 0.194 |
hERG Blockers: | 0.032 | Human Hepatotoxicity (H-HT): | 0.777 |
Drug-inuced Liver Injury (DILI): | 0.902 | AMES Toxicity: | 0.204 |
Rat Oral Acute Toxicity: | 0.812 | Maximum Recommended Daily Dose: | 0.918 |
Skin Sensitization: | 0.048 | Carcinogencity: | 0.961 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.835 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002536 | ![]() |
1.000 | D00ETS | ![]() |
0.221 | ||
ENC002052 | ![]() |
0.738 | D06HBQ | ![]() |
0.219 | ||
ENC004071 | ![]() |
0.718 | D0C7JF | ![]() |
0.213 | ||
ENC005468 | ![]() |
0.688 | D06XZW | ![]() |
0.211 | ||
ENC004946 | ![]() |
0.687 | D06YFA | ![]() |
0.206 | ||
ENC004943 | ![]() |
0.676 | D08UMH | ![]() |
0.205 | ||
ENC004072 | ![]() |
0.629 | D0D2VS | ![]() |
0.205 | ||
ENC002538 | ![]() |
0.621 | D05AFR | ![]() |
0.204 | ||
ENC003383 | ![]() |
0.600 | D03WAJ | ![]() |
0.203 | ||
ENC004948 | ![]() |
0.573 | D01CKY | ![]() |
0.201 |